about
Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitormiRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltrationRevisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures.How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma.Two independent epigenetic biomarkers predict survival in neuroblastomaClinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group projectA comparison of current neuroblastoma chemotherapeutics.Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.Vascular patterns provide therapeutic targets in aggressive neuroblastic tumorsSolid ovarian tumours in childhood: a 35-year review in a single institution.Treatment of high-risk neuroblastoma with anti-GD2 antibodies.Emerging drugs for neuroblastoma.Paediatric tumour boards in Spain: a national survey.Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma.Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application.Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas.Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?Herpesvirus-6 encephalitis complicated by Wernicke-Korsakoff syndrome in a pediatric recipient of unrelated cord blood transplantation.Hepatosplenic candidiasis in children with acute leukemia.Cancer in children and adolescents in Spain: incidence, treatment setting and provider specialty.Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.The International Neuroblastoma Risk Groups (INRG): a preliminary report.The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.miR-200c and phospho-AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis.Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.Immunosuppression. Role on the infectious diseases of oncologic children.Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors.Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma.
P50
Q28534151-3ED94D88-B14D-4D3B-A7F0-C81BEFA22696Q33559546-FD38163C-FC2B-4735-A056-B2296810C15FQ33735456-DE580104-FE50-478F-A53B-C015BBAD8F5AQ34032065-6EBF986B-70AE-4C4D-B86D-DC4146931B4CQ34121964-DC4261FE-5BBF-4C4A-BC70-5A882C682CA7Q34346730-8949FF4A-73F6-4DB3-B691-7BE3A7DE1F52Q34351596-EECD9B05-6E6F-414F-985A-D88FC339AAD9Q34558670-D0D4FC41-FC0E-4720-856F-933206596A54Q34606771-453AFE50-4B23-4D14-B6B8-4F998E486FDBQ34785880-5C74705F-7A71-4C44-BBFF-99EDFC07DAAAQ35108352-C9D1503E-2CD6-4987-98F9-2F085A605349Q35170598-10334660-A61E-4A82-BE8C-3C270BC8BC1BQ35172207-428F958C-A53B-44B9-B416-8166D4264D72Q35609684-7735AB39-3E36-43E5-BFB5-B313C16D3360Q35653969-70D8CC43-52C7-496F-83B0-BCE87F0F24F8Q36936057-ECA06F5C-E8B2-402F-8632-5A81F02EF6AEQ37190218-E590B45C-8F74-46D8-A62C-15FC87A7ACCAQ37750067-3789873F-F406-4B32-AD43-C807047C4384Q37820755-47BB12C7-A1A5-455B-A56B-AD83C5460EECQ38108399-B12B5846-1FD2-4C92-8CA1-2C9D6830C201Q38384214-0820EBED-522B-4178-80F9-183EEE55C3ACQ38758942-D4E45A1E-56A6-40D0-B176-43B2935BA926Q39319798-7CBFB740-BA93-47BA-BB38-877A0B61560AQ39592676-7298E15E-001B-47D3-BF8D-66E167EB3826Q39866458-FD6E1A0A-9442-463B-B999-4DD062BA1D2CQ40586361-2907C7D9-6A07-4979-B9AB-BB2CADE5C294Q40764959-7971E4ED-D3FB-4FD6-8001-5DC760EB1FA6Q40800299-B49C71B6-E3E5-4EC7-B85A-3466D7B601ABQ40881350-2D99E43B-1A65-4AAE-818A-CE889CA199E0Q41727691-A4122C90-B6F4-4A92-9587-3FF14EE538BCQ41883212-E0C3052E-D949-4FB5-BAF5-610B0F457BA2Q41975973-5FDB0B84-E122-43FE-B3CA-BCD26F35C264Q43608093-92924396-9E9F-41D8-94BB-B62647EBA962Q44041797-439C4B3A-6193-430A-92E0-D7AC84D72F8CQ44189835-DA2A5B3B-4EAF-465E-AB5C-D25B712C39AEQ44747351-E34C9490-2C03-4B5A-A466-7CEFBAFD0063Q44885393-0F51DF39-41B5-436A-9F77-A440A410DC8EQ45109290-E96D483A-6FBE-4D2E-BE5A-BD7C71F452E2Q45138010-2EC989A6-BC36-4CD6-8F99-0DC4ECB4350CQ45267671-3BC75388-FDC2-4C37-A76C-8B2EBF120E69
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Victoria Castel
@ast
Victoria Castel
@en
Victoria Castel
@es
Victoria Castel
@nl
Victoria Castel
@sl
type
label
Victoria Castel
@ast
Victoria Castel
@en
Victoria Castel
@es
Victoria Castel
@nl
Victoria Castel
@sl
prefLabel
Victoria Castel
@ast
Victoria Castel
@en
Victoria Castel
@es
Victoria Castel
@nl
Victoria Castel
@sl
P106
P21
P31
P496
0000-0002-3792-0615